Center for Targeted Therapeutics

描述（由申请人提供）：拟议中的靶向治疗中心（CTT）是南卡罗来纳大学（USC）的生物医学研究卓越中心（COBRE），其主要目标是吸引和培养有才华的初级科学家的专业发展，他们有动机在严重疾病的治疗方面做出改变。CTT将设在南卡罗来纳大学（USC）和南卡罗来纳医科大学（MUSC）的SC药学院（SCCP），目标教师之一是南加州大学医学院（SOM）。该中心的业务包括四个研究项目，由四名目标初级教员（两名在南加州大学sccp，一名在MUSC-SCCP，一名在南加州大学som）领导，他们在功能基因组学，药物发现，神经科学和纳米颗粒药物递送方面具有专业知识。该项目还将包括三个资源核心：功能基因组学核心（USC-SCCP）、合成化学和药物发现核心（MUSC-SCCP）以及显微镜和流式细胞术核心（USCSCCP），每个核心由一名主任和一名联合主任管理，他们将在项目开发中提供科学和智力建议，以及技术支持。每个项目都将使用每个核心，除了一个基于MUSC的项目，将不使用USC的显微镜和流式细胞术核心。CTT将利用南加州大学和南加州大学药学院现有的整合优势，这是两所大学共享的独特位置，在两个校区都有强大的组成部分，以及一个发达的视频通信系统，允许无缝通信和共享教学和研究项目。CTT将充分利用这两个机构的资源，这两个机构的药物发现和转化研究是非常重要的优先事项，并且还将与已经到位的IDeA项目进行对接。CTT保护伞将涵盖对靶向治疗至关重要的几个科学领域，并跨越多种疾病，其中包括与南卡罗来纳州人口特别相关的癌症和神经系统疾病。

DESCRIPTION (provided by applicant): The principal goal of the proposed Center for Targeted Therapeutics (CTT), a Center of Biomedical Research Excellence (COBRE) at the University of South Carolina (USC), is to attract and foster the professional development of talented junior scientists, who are motivated to make a difference in the treatment of serious diseases. The CTT will be located at the SC College of Pharmacy (SCCP) at the University of South Carolina (USC) and the Medical University of South Carolina (MUSC), with one of the target faculty at the USC School of Medicine (SOM). The Center operations include four research projects led by four target junior faculty members (two at USC-SCCP, one at MUSC-SCCP and one at USC-SOM), with expertise in functional genomics, drug discovery, neuroscience and nanoparticle drug delivery. The Program will also include three resource cores: the Functional Genomics Core (USC-SCCP), the Synthetic Chemistry and Drug Discovery Core (MUSC-SCCP) and the Microscopy and Flow Cytometry Core (USCSCCP), each managed by a Director and a co-Director, who will provide scientific and intellectual advice in project development, along with technological support. Each of the projects will be working with each of the cores, except that one project, based at MUSC, will not utilize the Microscopy and Flow Cytometry core at USC. The CTT will take advantage of the existing integration between USC and MUSC in the South Carolina College of Pharmacy, which is in the unique position of being shared between the two Universities, with strong components on both campuses, and a well-developed system of video communication that allows for seamless communication and sharing of teaching and research programs. The CTT will be well-positioned to take full advantage of the resources of both institutions, where drug discovery and translational research are strong priorities, and also interface with IDeA programs already in place. The CTT umbrella will encompass several scientific areas critical for targeted therapeutics and spanning multiple diseases among which are cancer and neurologic disorders that are particularly relevant to the South Carolina population.